Asuragen To Strengthen Affymetrix Diagnostic Product Portfolio
The RNA control kits, manufactured under cGMP, will enable Affymetrix to deliver a complete solution to its molecular diagnostic partners. The products will be configured for use with

The RNA control kits, manufactured under cGMP, will enable Affymetrix to deliver a complete solution to its molecular diagnostic partners. The products will be configured for use with

Epeius claimed that the Epeius VPU is poised to launch the large-scale production of targeted genetic medicine into the 21st century, in accordance with an FDA Critical Path

Zyto’s SMP program teams Zyto with nutriceutical suppliers who serve healthcare professionals exclusively. Vaughn Cook, CEO of Zyto, said: “The SMP program is a joint effort between Zyto

The consolidation of DSP’s two North American businesses serves to solidify DSP’s North American operations into one combined center of excellence. The unification of DSPA and Sepracor brings

FDA priority review status is granted to therapies that offer major advances in treatment or provide a treatment where no adequate therapy exists. This status accelerates the standard

EMB will acquire a license from Lonza on two key products: the Lonza Development Microreactor (process development) and Lonza Advanced Production Microreactors (manufacturing). As a result, EMB will

GSK and makers of the other affected medicines containing LABAs have 30 days to agree with the proposed changes or state why they are not warranted. The FDA’s

The study has demonstrated that VRX1023 is capable of achieving control of viral load over the course of four months following a challenge with a pathogenic simian immunodeficiency

Loprox (Ciclopirox Shampoo, 1%) is an antifungal indicated for the treatment of seborrheic dermatitis of the scalp in adults. According to Wolters Kluwer data, estimated annual brand sales

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections. Reportedly, Roche has started a 24 weeks Phase 2b study